Macrogenics (MGNX) Misses Q3 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Macrogenics (MGNX) Misses Q3 EPS by 17c

MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results

November 2, 2016 4:01 PM EDT

Continued expansion and advancement of product candidatesPortfolio update planned for upcoming R&D Day on December 13, 2016

ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today provided a corporate progress update and reported financial results for the quarter ended September 30, 2016.

MacroGenics continues to make progress across its broad pipeline of clinical compounds,... More